Short answer
ClearPoint Neuro, Inc. (CLPT) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $9M (up 9.1% year over year) with net income of −$6M.
Q3 2025 key financials · XBRL
- Revenue
- $9M
- +9.1% YoY · −3.8% QoQ
- Net income
- −$6M
- −18.4% YoY · −0.9% QoQ
- Operating margin
- -59.5%
- Gross margin
- 63.2%
- EPS (diluted)
- −$0.21
- −16.7% YoY · −5.0% QoQ
Source: XBRL data from the ClearPoint Neuro, Inc. (CLPT) Q3 2025 10-Q on SEC EDGAR. USD.
ClearPoint Neuro, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New merger-integration risk triggered by November 6, 2025 IRRAS agreement, including $5.0 million cash and 1,325,000 shares at closing
- Regulatory risk from evolving FDA CGT standards, potentially requiring additional studies, data, or post-marketing obligations
- Operational risk from delayed CGT approvals, postponing customer launches and anticipated product order volumes
- Financial risk from $30.5 million 2025 NPA debt outstanding at September 30, 2025
- Compliance risk from 2025 NPA covenants restricting debt, liens, acquisitions, dividends, stock repurchases, and investments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ClearPoint Neuro, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.